ReviewTransfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie2019
CAR-Expressing Natural Killer Cells for Cancer Retargeting.
Review in Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed.
- Current Developments of CAR-T and CAR-NK Cell Therapies for Ovarian Cancer.Stem cell reviews and reports · 2026Review
- Generation of the augmented IL-15-secreting anti-HER2 chimeric antigen receptor (CAR)-NK cells: an encouraging immunotherapeutic tool.Molecular biology reports · 2025Article
- CAR-NK, a Splendid Strategy for Cancer, Especially for Gynecologic Tumor.Immunity, inflammation and disease · 2025Review
- Evaluating the Influence of Different Serum-Free Culture Conditions on the Production and Function of Natural Killer Cell-Derived Extracellular Vesicles.Journal of extracellular biology · 2025Article
- Prospects for potential therapy targeting immune‑associated factors in endometriosis (Review).Molecular medicine reports · 2025Review
- Non-viral approaches in CAR-NK cell engineering: connecting natural killer cell biology and gene delivery.Journal of nanobiotechnology · 2024Review
- A new vision of the efficacy of both CAR-NK and CAR-T cells in treating cancers and autoimmune diseases.Medical oncology (Northwood, London, England) · 2024Review
- Augmenting the Antitumor Efficacy of Natural Killer Cells via SynNotch Receptor Engineering for Targeted IL-12 Secretion.Current issues in molecular biology · 2024Article
- Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting.Blood reviews · 2023Review
- Efficient Redirection of NK Cells by Genetic Modification with Chemokine Receptors CCR4 and CCR2B.International journal of molecular sciences · 2023Article
- Reovirus infection of tumor cells reduces the expression of NKG2D ligands, leading to impaired NK-cell cytotoxicity and functionality.Frontiers in immunology · 2023Article
- The peculiar challenge of bringing CAR-T cells into the brain: Perspectives in the clinical application to the treatment of pediatric central nervous system tumors.Frontiers in immunology · 2023Review
- NK-92 cells retain vitality and functionality when grown in standard cell culture conditions.PloS one · 2022Article
- The Biological Role and Therapeutic Potential of NK Cells in Hematological and Solid Tumors.International journal of molecular sciences · 2021Review
- Neglected No More: Emerging Cellular Therapies in Traumatic Injury.Stem cell reviews and reports · 2021Review
- In Situ Programming of CAR T Cells.Annual review of biomedical engineering · 2021Review
- Current and future treatment strategies in chronic lymphocytic leukemia.Journal of hematology & oncology · 2021Review
- [CAR T cells as drugs for novel therapies (advanced therapy medicinal products)].Der Internist · 2021Review
- Optimizing the Procedure to Manufacture Clinical-Grade NK Cells for Adoptive Immunotherapy.Cancers · 2021Article
- Clinical development of natural killer cells expressing chimeric antigen receptors.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the approval in 2017 and the outstanding success of Kymriah® and Yescarta®, the number of clinical trials investigating the safety and efficacy of chimeric antigen receptor-modified autologous T cells has been constantly rising. Currently, more than 200 clinical trials are listed on clinicaltrial.gov. In contrast to CAR-T cells, natural killer (NK) cells can be used from allogeneic donors as an "off the shelf product" and provide alternative candidates for cancer retargeting. This review summarises preclinical results of CAR-engineered NK cells using both primary human NK cells and the cell line NK-92, and provides an overview about the first clinical CAR-NK cell studies targeting haematological malignancies and solid tumours, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.